Abstract: The present invention relates to a method for manufacturing a labyrinth seal for a turbine through the additive manufacturing of martensitic stainless steel using 3D printing, the method including the steps of: making a ring-shaped body of the labyrinth seal by means of centrifugal casting or a ring mill and a labyrinth part protruding from one surface of the ring-shaped body of the labyrinth seal by means of the 3D printing; and depositing a bonding layer onto top of the ring-shaped body to improve a bonding force between the ring-shaped body and the labyrinth part, the bonding layer having a composition similar to the composition of the metal powder or metal wire used in the 3D printing.

Abstract: A method of manufacturing a labyrinth sealing device mounted between a diaphragm and a turbine rotor of a turbine to induce smooth rotation of the turbine rotor and prevent a leakage of gas by minimizing friction is presented. A labyrinth sealing device includes a ring-shaped body and a labyrinth part protruding from one surface of the ring-shaped body. The ring-shaped body is manufactured by centrifugal casting or ring mill, and the labyrinth part is manufactured by 3D printing.

Abstract: A device configured for a vehicle for supporting and massaging a neck of a passenger is provided. The device is configured such that a neck support pad is integrally formed on a lower end portion of a headrest to hold up and support the neck of a passenger, and a massage device is mounted in the neck support pad to massage the neck of the passenger, thus stably supporting and massaging the neck of the passenger sitting on a seat.

Abstract: Disclosed are a hybrid electric vehicle and a method for controlling an engine speed of a hybrid electric vehicle. In particular, the method includes: determining, when an engine on one end and a first motor are directly connected and while driving in a state where an engine clutch is connected and a second motor is connected to the other end, a compensation value based on the difference in the rotational speed of the engine and the second motor when a control entry is caused, which induces the rotational speed mismatch of the engine and the second motor; and compensating an output torque of the first motor based on the compensation value.

Abstract: Disclosed is a hybrid electric vehicle and a method of controlling an engine stop for the vehicle. The method includes: determining whether a first condition and a second condition is satisfied; applying a negative torque to the motor when the first condition and the second condition are satisfied; predicting occurrence of reverse rotation of the engine; and applying a feedback torque for satisfying the target behavior of the engine to the motor when the occurrence of the reverse rotation is predicted.

Abstract: The present invention relates to a method of manufacturing a labyrinth sealing device mounted between a diaphragm and a turbine rotor of a turbine in order to induce smooth rotation of the turbine rotor and prevent a leakage of gas by minimizing friction between a rotor, such as the turbine rotor, and a stator, such as the diaphragm, when the rotor rotates in the stator, wherein the labyrinth sealing device includes a ring-shaped body and a labyrinth part protruding from one surface of the ring-shaped body, the ring-shaped body is manufactured by centrifugal casting or ring mill, and the labyrinth part is manufactured by 3D printing. The method of manufacturing a labyrinth sealing can improve productivity by reducing material costs and machining costs by manufacturing the labyrinth part (or teeth) protruding from the ring-shaped body using three-dimensional printing after manufacturing the ring-shaped body by centrifugal casting or ring mill.

Abstract: A new synthesized non-peptide cationic oligo-guanidinium dendrimers containing a number of positive charges, 6, 9, 12, and 18 for use as antimicrobial agents and a method for synthesizing non-peptide cationic oligo-guanidinium dendrimers G12 and G18. These designed and synthesized dendrimers exhibit antimicrobial activities as well as biofilm disrupting activity against various pathogens such as Gram-negative bacteria, Gram-positive bacteria, and fungi. The application of these dendrimers are very broad, which includes application to pharmaceutical compounds that are covalently or non-covalently complexed. These combinations are important in helping the body reach the proper immune balance required for maximized function and/or optimal health.

Abstract: A nutritional supplement containing specific natural ingredients and composition to target cancer vulnerability. The supplement includes between 100 to 300 mg Fucoidan, between 5 and 20 mg Lutein, between 5 and 20 mg Lycopene, between 100 and 300 mg Curcumin, between 5 and 20 mg Astaxantin, between 10 and 100 mg of Siberian Chaga extract powder and between 50 and 200 mg Vitamin C, natural vitamin C from Acerola Cherry, Astaxanthin extract (96%), Curcumin (95%), Lycopene extract (96%), Lutein extract (80%), Siberian Chaga extract, and Fucoidan extract from a brown algae, Undaria pinnatifida. The administration of combinations of these nutrients in set ratio increase anti-cancer activities and the body's ability to prevent cancer. These combinations are also important in helping the body reach the proper immune balance required for maximized function and/or optimal health. All amounts by weight.

Abstract: The invention relates generally to the changes in gene expression in human tissues from cancer patients. The invention relates specifically to human gene families which are differentially expressed in cancer tissues of breast, colon, esophagus, kidney, liver, lung, lymph node, ovary, pancreas, prostate, rectum, and/or stomach compared to corresponding normal tissues.

Abstract: Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

Abstract: The present invention results from the examination of tissue from hepatic carcinomas to identify genes differentially expressed between cancerous liver tissue and diseased but non-cancerous liver tissue. The invention includes diagnostic, screening, drug design and therapeutic methods using these genes, as well as solid supports comprising oligonucleotide arrays that are complementary to or hybridize to the differentially expressed genes.

Abstract: The invention relates generally to the changes in gene expression in hepatocellular carcinoma. The invention relates specifically to human genes that correspond to mRNA species that are differentially expressed in cancerous liver tissue and in cancerous neoplasms compared to non-cancerous liver tissue.

Abstract: The present invention results from the examination of tissue from stomach tumors to identify genes that are differentially expressed between cancerous and normal tissue. The invention includes diagnostic, monitoring, drug design and therapeutic methods using these genes, as well as solid supports comprising oligonucleotide arrays that are complementary to or hybridize to the differentially expressed genes.

Abstract: The invention relates generally to the changes in gene expression in human tissues from cancer patients. The invention relates specifically to human gene families which are differentially expressed in cancer tissues of breast, colon, esophagus, kidney, liver, lung, lymph node, ovary, pancreas, prostate, rectum, and/or stomach compared to corresponding normal tissues.

Abstract: The invention relates generally to the changes in gene expression in stomach cancer. The invention relates specifically to human gene families that correspond to mRNA species that are differentially expressed in cancerous stomach tissue compared to normal stomach tissue.

Abstract: The present invention provides to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. The present invention also provides a pharmaceutical composition for preventing inflammation and apoptosis which comprise the isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof and the process for preparing the same. The derivative according to the present invention can be effectively used in treating diseases due to caspases, such as, for example the disease in which cells are abnormally died, dementia, cerebral stroke, AIDS, diabetes, gastric ulcer, hepatic injury by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflammation.

Abstract: A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”) is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.

Abstract: The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compounds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compounds and pharmaceutical compositions comprising these compounds.

Abstract: The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase(CDK). The present invention also relates to an agent for inhibiting and treating diseases involving cell proliferation, e.g., cancer, inflammation, restenosis, angiogenesis, etc. which comprises the compound of formula (1) as an active ingredient together with a pharmaceutically acceptable carrier.

Abstract: The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase (CDK). The present invention also relates to an agent for inhibiting and treating diseases involving cell proliferation, e.g., cancer, inflammation, restenosis, angiogenesis, etc. which comprises the compound of formula (1) as an active ingredient together with a pharmaceutically acceptable carrier.